Epharmix, Inc. — Form D
Epharmix, Inc. of ST. LOUIS, MO, a company, filed a Form D exempt-offering notice with the SEC on 2018-09-07. The offering totals $3.0M, of which $1.9M was reported sold. Industry: Other Technology.
Offering
- Filed: 2018-09-07
- Form: D
- Accession: 0001648841-18-000001
- Industry: Other Technology
- Exemptions: 06b
- Total offering: $3.0M
- Amount sold: $1.9M
- Remaining: $1.1M
- Investors: 6
- Date of first sale: 2018-05-30
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-320889
Issuer
- Name: Epharmix, Inc.
- CIK: 0001648841
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2015
- Address: 4220 Duncan Ave, ST. LOUIS, MO, 63110
- Phone: 925-899-2669
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Mark Bakken | Director | Madison, WI |
| Avik Som | Director | Allston, MA |
| Avik Som | Executive Officer | Allston, MA |
| Avik Som | Promoter | Allston, MA |
| Charles Bolton | Director | St. Louis, MO |
| Blake Marggraff | Director | St. Louis, MO |
| Blake Marggraff | Executive Officer | St. Louis, MO |
| Blake Marggraff | Promoter | St. Louis, MO |
| Max Bricklin | Director | St. Louis, MO |
| Yiteng Huang | Director | St. Louis, MO |
| Yiteng Huang | Promoter | St. Louis, MO |
Other filings by this issuer (2)
More